The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Open accessAbstract
Background Ramucirumab is a human IgG1 monoclonal antibody that targets the extracellular domain of VEGFR-2. We aimed to assess efficacy and safety of treatment with docetaxel plus ramucirumab or placebo as second-line treatment for patients with stage IV non-small-cell-lung cancer (NSCLC) after platinum-based therapy.Methods In this multicentre, double-blind, randomised phase 3 trial (REVEL), we enrolled patients with squamous or non-squamous NSCLC who had progressed during or after a first-line platinum-based chemotherapy regimen. Patients were randomly allocated (1:1) with a centralised, interactive voice-response system (stratified by sex, region, performance status, and previous maintenance therapy [yes vs no]) to receive docetaxel 75 mg/m(2) and either ramucirumab (10 mg/kg) or placebo on day 1 of a 21 day cycle until disease progression, unacceptable toxicity, withdrawal, or death. The primary endpoint was overall survival in all patients allocated to treatment. We assessed adverse events according to treatment received. This study is registered with ClinicalTrials.gov, number NCT01168973.Findings Between Dec 3, 2010, and Jan 24, 2013, we screened 1825 patients, of whom 1253 patients were randomly allocated to treatment. Median overall survival was 10·5 months (IQR 5·1-21·2) for 628 patients allocated ramucirumab plus docetaxel and 9·1 months (4·2-18·0) for 625 patients who received placebo plus docetaxel (hazard ratio 0·86, 95% CI 0·75-0·98; p=0·023). Median progression-free survival was 4·5 months (IQR 2·3-8·3) for the ramucirumab group compared with 3·0 months (1·4-6·9) for the control group (0·76, 0·68-0·86; p<0·0001). We noted treatment-emergent adverse events in 613 (98%) of 627 patients in the ramucirumab safety population and 594 (95%) of 618 patients in the control safety population. The most common grade 3 or worse adverse events were neutropenia (306 patients [49%] in the ramucirumab group vs 246 [40%] in the control group), febrile neutropenia (100 [16%] vs 62 [10%]), fatigue (88 [14%] vs 65 [10%]), leucopenia (86 [14%] vs 77 [12%]), and hypertension (35 [6%] vs 13 [2%]). The numbers of deaths from adverse events (31 [5%] vs 35 [6%]) and grade 3 or worse pulmonary haemorrhage (eight [1%] vs eight [1%]) did not differ between groups. Toxicities were manageable with appropriate dose reductions and supportive care.Interpretation Ramucirumab plus docetaxel improves survival as second-line treatment of patients with stage IV NSCLC.Funding Eli Lilly.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The median overall survival was estimated at 12.5 months, which compares favorably to historical benchmarks in this disease setting (i.e. docetaxel combined with ramucirumab had 10.5 months overall survival in the REVEL study)32.”
From Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes (2021) · cites this paper as [32]
In the citing paper
“The median overall survival was estimated at 12.5 months, which compares favorably to historical benchmarks in this disease setting (i.e. docetaxel combined with ramucirumab had 10.5 months overall survival in the REVEL study)32.”
From Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes (2021) · cites this paper as [32]
In the citing paper
“The study compared docetaxel with ramucirumab or placebo in patients who had progressed after platinum-based chemotherapy.Median OS was longer (10.5 versus 9.1 months, HR 0.86, 95% CI: 0.75-0.98,P = 0.023) in the ramucirumab arm compared with the placebo arm.Median PFS was also superior in the ramucirumab arm”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [94]
In the citing paper
“One trial tested a new vascular endothelial growth factor inhibitor for NSCLC, ramucirumab (plus docetaxel); the intervention arm experienced longer PFS (by 1.5 months) and OS (by 1.4 months), both statistically significant.”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [57]
In the citing paper
“Hematologic adverse events were more frequent with ramucirumab plus docetaxel, as were other adverse events, such as diarrhea, dyspnea, and fatigue.57”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [57]
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Self-citationHanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Shepherd, F. A., Dancey, J. E., Ramlau, R., Mattson, K. V., Gralla, R. J., O’Rourke, M. A., Levitan, N. I., Gressot, L., Vincent, M. D., Burkes, R. L., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.10.2095 · Cited by 2,178
Fuchs, C., Tomášek, J., Cho, J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., dos Santos, L. D., Aprile, G., Ferry, D., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61719-5 · Cited by 2,031
Self-citationJohnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S., Nemunaitis, J. J., Jablons, D. M., Langer, C. J., DeVore, R. F., Gaudreault, J., Damico, L. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.022 · Cited by 1,948
Research works printed but not linked: 1
- Wilke, 2014, J Clin Oncol, 32
Cited by
Sorted by citations
Items 501–600 of 1,001
Yu, L., Xu, J., Qiao, R., Zhong, H., Brueckl, W. M., & Zhong, R. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-260 · Cited by 15
International Cost-Effectiveness Analysis of Durvalumab in Stage III Non–Small Cell Lung Cancer
Kareff, S. A., Han, S., Haaland, B. A., Jani, C., Kohli, R., Aguiar, P. N., Huang, Y., Soo, R. A., Rodríguez-Pérez, Á., García‐Foncillas, J., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.13938 · Cited by 18
Receptor tyrosine kinases in breast cancer treatment: unraveling the potential
Yu, Q. (2024) · American Journal of Cancer Research · doi:10.62347/kivs3169 · Cited by 19
Calvetti, L., Pilotto, S., Carbognin, L., Ferrara, R., Caccese, M., Tortora, G., & Bria, E. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1071350 · Cited by 16
Giampieri, R., Caporale, M., Pietrantonio, F., de Braud, F., Negri, F., Giuliani, F., Pusceddu, V., Demurtas, L., Restivo, A., Fontanella, C., et al. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.02.005 · Cited by 15
Incorporation of Antiangiogenic Therapy Into the Non–Small-Cell Lung Cancer Paradigm
Chu, B. F., & Otterson, G. A. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.05.020 · Cited by 15
Greillier, L., Tomasini, P., & Barlési, F. (2016) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465816652083 · Cited by 15
Armoiry, X., Tsertsvadze, A., Connock, M. J., Royle, P., Meléndez‐Torres, G. J., Souquet, P.-J., & Clarke, A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0199575 · Cited by 15
Combination of Immunotherapy and Antiangiogenic Therapy in Cancer—a Rational Approach
Padda, S. K., & Reckamp, K. L. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.11.007 · Cited by 15
Ishida, M., Morimoto, K., Yamada, T., Shiotsu, S., Chihara, Y., Yamada, T., Hiranuma, O., Morimoto, Y., Iwasaku, M., Tokuda, S., et al. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14236 · Cited by 15
Jin, S., Yang, Y., Ma, Y., Yang, B., Zhang, Y., Kang, S., Zhou, T., Hong, S., Qin, T., Hu, Z., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127306 · Cited by 15
Into the Clinic With Nivolumab and Pembrolizumab
Shu, C. A., & Rizvi, N. A. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0099 · Cited by 15
Afatinib in Non-Small Cell Lung Cancer.
Wirth, S. M. (2015) · Europe PMC (PubMed Central) · Cited by 15
Stratified Treatment in Lung Cancer
Michels, S. Y. F., & Wolf, J. (2016) · Oncology Research and Treatment · doi:10.1159/000453406 · Cited by 15
Tambo, Y., Hosomi, Y., Sakai, H., Nogami, N., Atagi, S., Sasaki, Y., Kato, T., Takahashi, T., Seto, T., Maemondo, M., et al. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0435-2 · Cited by 15
Iwama, E., Nakanishi, Y., & Okamoto, I. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1432356 · Cited by 15
Zhang, S., Han, C., Sun, L., Huang, L., & Ma, J. (2020) · Radiation Oncology · doi:10.1186/s13014-020-01646-9 · Cited by 15
Asano, J., Sugano, H., Murakami, H., Noguchi, A., Ando, Y., & Uyama, Y. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3540 · Cited by 15
Lu, J. G., Hu, M., Zhao, Y., Chu, T., Zhang, W., Zhou, Y., Cai, X., Wu, J., Hu, L., Shi, C., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02382-w · Cited by 14
Gridelli, C., Besse, B., Brahmer, J. R., Crinò, L., Felip, E., & de Marinis, F. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.01.004 · Cited by 15
Bertaglia, V., Vallone, S., Pacchiana, M. V., & Novello, S. (2017) · Lung Cancer Management · doi:10.2217/lmt-2017-0011 · Cited by 14
Chen, J.-H., Yang, J.-L., Chou, C., Wang, J., & Hung, C. (2018) · Scientific Reports · doi:10.1038/s41598-018-27994-x · Cited by 14
Hasegawa, T., Okuyama, T., Uemura, T., Matsuda, Y., Otani, H., Shimizu, J., Horio, Y., Watanabe, N., Yamaguchi, T., Fukuda, S., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac178 · Cited by 14
Angiogenic inhibitor pre‐administration improves the therapeutic effects of immunotherapy
Sato, M., Maishi, N., Hida, Y., Yanagawa‐Matsuda, A., Alam, M. T., Sakakibara‐Konishi, J., Nam, J., Onodera, Y., Konno, S., & Hida, K. (2023) · Cancer Medicine · doi:10.1002/cam4.5696 · Cited by 13
Matsuzawa, R., Morise, M., Ito, K., Hataji, O., Takahashi, K., Koyama, J., Kuwatsuka, Y., Gotô, Y., Imaizumi, K., Itani, H., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102303 · Cited by 15
Aokage, K., Koyama, S., Kumagai, S., Nomura, K., Shimada, Y., Yoh, K., Wakabayashi, M., Fukutani, M., Furuya, H., Miyoshi, T., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1561 · Cited by 15
NCCN Guidelines Version 1.2015 Panel Members Non-Small Cell Lung Cancer
Ettinger, D. S., Kimmel, S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., Jahan, T. M., et al. (2014) · Cited by 14
Morabito, A. (2018) · BMC Medicine · doi:10.1186/s12916-018-1011-0 · Cited by 14
Frega, S., Bonanno, L., Guarneri, V., Conte, P., & Pasello, G. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.05.013 · Cited by 14
Efficacy of icotinib in advanced lung squamous cell carcinoma
Liang, S., Xu, Y., Tan, F., Ding, L., Ma, Y., & Wang, M. (2018) · Cancer Medicine · doi:10.1002/cam4.1736 · Cited by 13
Ma, J., Sun, J., Sun, L., Zhang, S., Huang, L., & Han, C. (2018) · Medicine · doi:10.1097/md.0000000000012083 · Cited by 14
Peravali, M., Wang, H., Kim, C., & Veytsman, I. G. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00981-0 · Cited by 15
Pollack, M. L. H., Keating, K. N., Wissinger, E., Jackson, L., Sarnes, E., & Cuffel, B. J. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1847057 · Cited by 15
The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer
Wang, F., Jin, F., Cheng, B., Zhang, Y., Zhou, Q. H., & Wang, S. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03752-x · Cited by 14
Biomarkers in the management of lung cancer: changing the practice of thoracic oncology
Melichar, B. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2022-1108 · Cited by 15
Anti-EGFR and antiangiogenic monoclonal antibodies in metastatic non-small-cell lung cancer
Losanno, T., Rossi, A., Maione, P., Napolitano, A., & Gridelli, C. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1163333 · Cited by 16
Tiwari, P. (2016) · Journal of the Egyptian National Cancer Institute · doi:10.1016/j.jnci.2016.03.001 · Cited by 15
Anzai, M., Morikawa, M., Okuno, T., Umeda, Y., Demura, Y., Sonoda, T., Yamaguchi, M., Kanno, K., Shiozaki, K., Ameshima, S., et al. (2017) · Medicine · doi:10.1097/md.0000000000009320 · Cited by 14
Morgensztern, D., Cobo, M., Ponce-Aix, S., Postmus, P. E., Lewanski, C. R., Bennouna, J., Fischer, J. R., Juan, Ó., Stewart, D. J., Fasola, G., et al. (2018) · Cancer · doi:10.1002/cncr.31779 · Cited by 14
Self-citationMouri, A., Kaira, K., Shiono, A., Yamaguchi, O., Murayama, Y., Kobayashi, K., & Kagamu, H. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13022 · Cited by 14
Schulz, C. K. J., Gandara, D. R., Berardo, C. G., Rosenthal, R., Foo, J., Morel, C., Ballinger, M. D., Watkins, C. L., & Chu, P. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.06.017 · Cited by 14
Treatment options after first-line immunotherapy in metastatic NSCLC
Santos, E. S. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1738930 · Cited by 14
Anti-angiogenic drugs for second-line treatment of NSCLC patients: just new pawns on the chessboard?
Bronte, G., Passiglia, F., Galvano, A., & Russo, A. G. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1075000 · Cited by 14
Targeting HER2 in lung cancers: Evolving treatment landscape and drug development strategies
Reinhorn, D. J., Moskovitz, M. T., Tap, W. D., & Li, B. T. (2025) · Cancer · doi:10.1002/cncr.35780 · Cited by 14
Reuss, J. E., Bazhenova, L. A., Ismaila, N., Rous, F. A., Ahluwalia, A., Alluri, K. C., Azar, I. H., Campbell, T., Durm, G. A., Feldman, J., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-02825 · Cited by 14
Antibody Drug Conjugates in Lung Cancer
Merle, G., Friedlaender, A., Desai, A. P., & Addeo, A. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000630 · Cited by 15
Masuda, T., Hirata, T., Sakamoto, T., Tsubata, Y., Ichihara, E., Kozuki, T., Shoda, H., Motonaga, M., Yoshida, T., Fukutani, M., et al. (2024) · Journal of Thoracic Disease · doi:10.21037/jtd-23-1858 · Cited by 13
Cross-omics strategies and personalised options for lung cancer immunotherapy
Yan, Y., Shen, S., Li, J., Su, L., Wang, B., Zhang, J., Lu, J., Luo, H., Han, P., Ke Cheng, X. U., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1471409 · Cited by 14
Steuer, C. E., Hayashi, H., Su, W., Nishio, M., Johnson, M. L., Kim, D., Massarelli, E., Felip, E., Gold, K. A., Murakami, H., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02744 · Cited by 13
Pharmacological management of relapsed/refractory NSCLC with chemical drugs
Karachaliou, N., Sosa, A. E., Barrón, F., Cao, M. G., Santarpía, M., & Rosell, R. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1285284 · Cited by 13
Second-line therapy of squamous non-small cell lung cancer: an evolving landscape
Lazzari, C., Karachaliou, N., Gregorc, V., Bulotta, A., González‐Cao, M., Verlicchi, A., Altavilla, G., Rosell, R., & Santarpía, M. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1326822 · Cited by 13
Sekine, A., & Satoh, H. (2017) · Medical Oncology · doi:10.1007/s12032-017-0978-2 · Cited by 13
Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation
Zeng, D., Wang, C.-G., Huang, J., & Jiang, J. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s139520 · Cited by 13
Prabhash, K. (2019) · South Asian Journal of Cancer · doi:10.4103/sajc.sajc_227_18 · Cited by 13
Self-citationSakaguchi, T., Furuya, N., Ito, K., Hida, N., Morikawa, K., Komase, Y., Inoue, T., Hataji, O., & Mineshita, M. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13429 · Cited by 13
Aix, S. P., Novello, S., Garon, E. B., Nakagawa, K., Nadal, E., Moro‐Sibilot, D., García, M. A., Fabre, E., Frimodt‐Moller, B., Zimmermann, A., et al. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100378 · Cited by 13
Self-citationMobocertinib: A Potential Treatment for NSCLC with EGFR Exon 20 Insertions
Pacheco, J. M. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0379 · Cited by 13
Xu, X., Li, R., Zhu, P., Zhang, P., Chen, J., Lin, Y., & Chen, Y. (2021) · World Journal of Surgical Oncology · doi:10.1186/s12957-021-02340-0 · Cited by 12
Osta, B. E. E., Carlisle, J. W., Steuer, C. E., Pakkala, S., Leal, T. A. B., Dhodapkar, M. V., Liu, Y., Chen, Z., Owonikoko, T. K., & Ramalingam, S. S. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.06.003 · Cited by 13
Baci, D., Cekani, E., Imperatori, A. S., Ribatti, D., & Mortara, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.914890 · Cited by 12
Therapies Targeting Immune Cells in Tumor Microenvironment for Non-Small Cell Lung Cancer
Ye, W., Li, M., & Luo, K.-W. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071788 · Cited by 14
Novel Therapies for Advanced Squamous Cell Carcinoma of the Lung
Koutsoukos, K., & Mountzios, G. (2016) · Future Oncology · doi:10.2217/fon.15.358 · Cited by 13
Cardiovascular Adverse Effects of Targeted Antiangiogenic Drugs: Mechanisms and Management
Sundararajan, S., Kumar, A., Poongkunran, M., Kannan, A., & Vogelzang, N. J. (2016) · Future Oncology · doi:10.2217/fon.16.4 · Cited by 13
Zaïr, Z. M., & Singer, D. R. J. (2016) · Pharmacogenomics · doi:10.2217/pgs-2015-0006 · Cited by 13
Second-Line Treatment of NSCLC—The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms
Köhler, J. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00009 · Cited by 13
Saudi lung cancer management guidelines 2017
Jazieh, A. R., Kattan, K. A., Bamousa, A., Olayan, A. A., Abdelwarith, A., Ansari, J., Al-Twairqi, A., Alfayea, T. M., Saleh, K. A., Husaini, H. A., et al. (2017) · Annals of Thoracic Medicine · doi:10.4103/atm.atm_92_17 · Cited by 12
Ci, H., Xu, Z., Xu, J., Wang, Y., & Wu, S. (2018) · Medicine · doi:10.1097/md.0000000000012293 · Cited by 13
Duan, J., Wang, Z., Lin, L., Li, J., Wang, Y., Bai, H., Hu, X., Liu, Y., Hao, X., Wang, H., et al. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00735-1 · Cited by 13
Reck, M., Kerr, K. M., Grohé, C., Manegold, C., Pavlakis, N., Paz-Ares, L. G., Huber, R. M., Popat, S., Thatcher, N., Park, K., et al. (2019) · Future Oncology · doi:10.2217/fon-2018-0948 · Cited by 13
Self-citationTamura, N., Horinouchi, H., Sekine, K., Matsumoto, Y., Murakami, S., Goto, Y., Kanda, S., Fujiwara, Y., Yamamoto, N., & Ohe, Y. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13055 · Cited by 13
Emerging angiogenesis inhibitors for non-small cell lung cancer
Malapelle, U., & Rossi, A. (2019) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2019.1619696 · Cited by 13
Kasahara, N., Sunaga, N., Kuwako, T., Naruse, I., Imai, H., Jingu, A., Tsukagoshi, Y., Masuda, T., Kitahara, S., Tsurumaki, H., et al. (2020) · Supportive Care in Cancer · doi:10.1007/s00520-020-05317-z · Cited by 13
Personalized chemotherapy of lung cancer: What the radiologist should know
Ferretti, G., Reymond, E., Delouche, A., Sakhri, L., Jankowski, A., Moro‐Sibilot, D., Lantuéjoul, S., & Toffart, A. (2016) · Diagnostic and Interventional Imaging · doi:10.1016/j.diii.2015.11.013 · Cited by 14
Chow, L. Q. M., Smith, D. C., Tan, A. R., Denlinger, C. S., Wang, D., Shepard, D. R., Chaudhary, A., Lin, Y., & Gao, L. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3098-3 · Cited by 13
Afatinib in the treatment of squamous non-small cell lung cancer: a new frontier or an old mistake?
Russo, G. L., Proto, C., & Garassino, M. C. (2016) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2015.12.02 · Cited by 14
50 Years of Progress in NSCLC: A New Fellow’s Guide in the Clinic
Naidoo, J., Niroula, A., Uprety, D., Smeltzer, M. P., Geissen, N. M., Osarogiagbon, R. U., Mino-Kenudson, M. A., Yatabe, Y., Higgins, K. A., Desai, A. P., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.06.028 · Cited by 13
Lisberg, A. E., Huppert, L. A., Halmos, B., Ledezma, B. A., Soto-Romano, V., & Traina, T. A. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf225 · Cited by 12
Planchard, D., Kim, H. R., Suksombooncharoen, T., Li, R., Cortinovis, D. L., Han, J., Samol, J., Runglodvatana, Y., Lee, K.-Y., Chang, G.-C., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.12.080 · Cited by 12
Efficacy and safety assessment of apatinib in patients with advanced gastric cancer: a meta-analysis
Chen, J., & Wang, J. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s157466 · Cited by 12
Divan, H. A., Bittoni, M. A., Krishna, A., & Carbone, D. P. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107177 · Cited by 12
A Review of FDA-Approved Multi-Target Angiogenesis Drugs for Brain Tumor Therapy
Buzatu, I. M., Tătăranu, L. G., Duţă, C., Stoian, I. A.-M., Alexandru, O., & Dricu, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052192 · Cited by 13
Angiogenesis causes and vasculogenic mimicry formation in the context of cancer stem cells
Li, Y., Liu, X., Dong, Y., & Zhou, Y. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189323 · Cited by 13
Identifying Blood-Based Protein Biomarkers for Antiangiogenic Agents in the Clinic
Hatch, A. J., Clarke, J. M., Nixon, A. B., & Hurwitz, H. I. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000129 · Cited by 12
Qi, W., Fu, S., Zhang, Q., & Guo, X. (2016) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.148700 · Cited by 12
Zugazagoitia, J., Díaz, A., Jiménez, E., Nuñez, J. A., Iglesias, L., Ponce-Aix, S., & Paz-Ares, L. G. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00036 · Cited by 12
Corke, L., & Sacher, A. G. (2021) · Current Oncology · doi:10.3390/curroncol29010004 · Cited by 15
Yang, M., Zhao, X., Li, B., Wang, Y., & Shi, X. (2022) · Current Cancer Drug Targets · doi:10.2174/1568009622666220629154619 · Cited by 12
Franco, A. O., Hodgson, C., Raja, H., Carter, M., Lindsay, C. R., Hughes, S., Cove-Smith, L., Taylor, P. D., Summers, Y., Blackhall, F. H., et al. (2022) · Targeted Oncology · doi:10.1007/s11523-022-00889-8 · Cited by 12
Olivier, T., Haslam, A., & Prasad, V. K. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101591 · Cited by 14
Wang, K., Qu, X. H., Wang, Y., Dong, W., Shen, H., Zhang, T., Ni, Y., Liu, Q., & Du, J. (2015) · Clinical Drug Investigation · doi:10.1007/s40261-015-0355-x · Cited by 12
Wu, F., Zhang, S., Gao, G., Zhao, J., Ren, S., & Zhou, C. (2017) · Cancer Biology & Therapy · doi:10.1080/15384047.2017.1414757 · Cited by 12
Ikeda, S., Kato, T., Ogura, T., Sekine, A., Oda, T., Masuda, N., Igawa, S., Katono, K., Otani, S., Yamada, K., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4150-y · Cited by 12
Hata, A., Harada, D., Okuda, C., Kaji, R., Masuda, Y., Takechi, Y., Kozuki, T., Nogami, N., & Katakami, N. (2018) · Oncotarget · doi:10.18632/oncotarget.25578 · Cited by 12
Lee, Y., Hsu, J.-F., & Yang, C. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.08.2031 · Cited by 12
Spagnuolo, A., Palazzolo, G., Sementa, C., & Gridelli, C. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1713092 · Cited by 12
Yu, Z., Cai, X., Xu, Z., He, Z., Lai, J., Wang, W., Zhang, J., Kong, W., Huang, X., Chen, Y., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0519 · Cited by 12
Lin, Y., Su, W., & Lan, G. (2020) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23338 · Cited by 12
RetractedLiang, J., Gu, W., Jin, J., Zhang, H., Chen, Z., Tang, Y., Zhang, S., Yang, S., Deng, Y., & Feng, W. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920968472 · Cited by 12
Kim, J., Cho, C.-K., & Yoo, H. (2016) · Integrative Cancer Therapies · doi:10.1177/1534735416639714 · Cited by 12
Self-citationLi, B. T., Barnes, T. A., Chan, D. L. H., Naidoo, J., Lee, A., Khasraw, M., Marx, G. M., Kris, M. G., Clarke, S. J., Drilon, A. E. D. C., et al. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.10.004 · Cited by 12
Metadata
- Authors
- Garon, E. B., Ciuleanu, T.-E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., Park, K., Gorbunova, V., Kowalyszyn, R. D., Pikiel, J., Czyzewicz, G., Orlov, S. V., Lewanski, C. R., Thomas, M., Bidoli, P., Dakhil, S., Gans, S., Kim, J.-H., Grigorescu, A., Karaseva, N., Reck, M., Cappuzzo, F., Alexandris, E., Sashegyi, A., Yurasov, S., & Pérol, M.
- Affiliations
- University of California, Los Angeles (US)
- Iuliu Hațieganu University of Medicine and Pharmacy (RO)
- Instituto Nacional de Cancerología (MX)
- Tata Memorial Hospital (IN)
- Sotiria General Hospital (GR)
- Samsung Medical Center (KR)
- Russian Cancer Research Center NN Blokhin (RU)
- Charing Cross Hospital (GB)
- University Hospital Heidelberg (DE)
- Azienda Ospedaliera San Gerardo (IT)
- Cancer Center of Kansas (US)
- Gemeinschaftskrankenhaus Herdecke (DE)
- Yonsei University Health System (KR)
- Institutul Oncologic Bucuresti (RO)
- City Clinical Oncology Center (RU)
- German Center for Lung Research (DE)
- Ospedale di Livorno (IT)
- Eli Lilly (United States) (US)
- Corresponding author
- Garon, Edward B
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2014-08
- Volume
- 384
- Issue
- 9944
- Pages
- 665-673
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2140980839
- Cited by
- 1,309
- References
- 35
- Citations by year
- 2026: 57 · 2025: 71 · 2024: 116 · 2023: 102 · 2022: 110 · 2021: 97 · 2020: 108 · 2019: 102 · 2018: 106 · 2017: 148 · 2016: 155 · 2015: 115 · 2014: 19
- FWCI
- 116.89
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- ramucirumab, docetaxel, non-small cell lung cancer, second-line therapy, VEGFR-2 inhibition, anti-angiogenic therapy, overall survival, progression-free survival, adverse events, drug safety, maintenance therapy, lung squamous cell carcinoma, non-squamous cell lung cancer
- MeSH terms
- Docetaxel, Ramucirumab, Adult, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Double-Blind Method, Female, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Placebos, Platinum, Quality of Life, Survival Rate, Disease Progression, Taxoids, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
